After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
This is the first update to the original CTS communication distributed on July 6th. As previously co...
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...
Through communications with our clients, CTS is aware of the current national blood shortage. We rea...
IPFA welcomes Marion Lanteri as Executive Board member, CTS as new member organization
As a reminder, CTS will be exhibiting this weekend at the AABB Annual Meeting in San Antonio, T...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...